Palantir Technologies Inc. is navigating a landscape of contrasting developments. The data analytics firm is simultaneously expanding its footprint within financial regulation while facing a setback in the American healthcare sector, highlighting its mixed operational fortunes.
Regulatory Technology Gains Traction with UK Watchdog
A significant step forward comes from the United Kingdom, where the Financial Conduct Authority (FCA) has initiated a three-month pilot program. The trial leverages Palantir’s Foundry platform in an effort to enhance the detection of financial crime. The system will be used to analyze sensitive datasets, including call recordings, email communications, case files, and social media posts, searching for patterns indicative of potential misconduct.
Privacy concerns surrounding the use of such data have been addressed by the regulator. The FCA has clarified that Palantir itself will have no access to the underlying data during the pilot and will not receive it upon the project’s conclusion.
This regulatory move coincided with another strategic announcement. Palantir and the global consultancy Bain & Company revealed an expansion of their partnership, focusing on AI-driven transformation initiatives across 65 cities and 40 countries. The collaboration will see over 1,500 Bain specialists deploying Palantir’s Artificial Intelligence Platform (AIP) and Foundry for enterprise clients.
Should investors sell immediately? Or is it worth buying Palantir?
US Healthcare Contract Fails to Renew
In a less favorable turn, Palantir’s presence in the US healthcare market has encountered a hurdle. New York City Health + Hospitals, the city’s public hospital network, has decided not to renew its contract with the company. The agreement, active since November 2023 and valued at approximately $4 million, utilized patient data for streamlining insurance billing processes.
This decision follows increasing scrutiny and pressure regarding Palantir’s involvement in health data projects. Despite this North American setback, the company maintains a pivotal contract in the United Kingdom: a £330 million deal with the National Health Service (NHS) for the Federated Data Platform. This agreement remains central to Palantir’s international growth strategy in the healthcare domain.
Financial Performance and Market Valuation
The company’s latest financial results demonstrate robust growth. For the fourth quarter of 2025, Palantir reported revenue of $1.41 billion, representing a substantial 70% year-over-year increase. Its earnings per share came in at $0.25, exceeding the analyst consensus estimate of $0.23.
Currently, the stock is trading roughly 13% below its 200-day moving average and has seen notable weakness since the start of the year. The consensus price target among market analysts stands at $198.59, with the equity generally rated as a moderate buy. The stock’s price-to-earnings ratio of 234 reflects the elevated growth expectations currently priced in by investors.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from March 28 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 28.
Palantir: Buy or sell? Read more here...
